Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 12, 2003, Pages 2531-2535

  Antovic, A ^a   Blomback M ^a   Bremme, K ^a   Rooijen, M Van ^a   He, S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

APC resistance; DVT recurrence; Factor V leiden mutation; Overall hemostasis potential

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; BLOOD CLOTTING TEST; CASE CONTROL STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RECURRENT DISEASE; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RECURRENCE; THROMBIN; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 1542544917     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2003.00451.x     Document Type: Article

References (23)

1. Bertina RM, Koelman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Valen PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
2. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor Vand the risk of myocardial infarction, stroke and venous thrombosis in appar-ently healthy men. N Engl J Med 1995; 332: 912-7.
3. Rosendaal FR, Koster T, Vanderbroucke JP, Retisma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
4. Bajzar L, Kalafatis M, Simoni P, Tracy PB. An antifibrinolytic mechan-ism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
5. Cumming AM, Tait RC, Fildes S, Yoong A, Kenny S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-7.
6. Henkens CMA, Born VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
7. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coag Fibrinol 1996; 7: 761-5.
8. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 797-8.
9. Clark P, Walker ID, Greer I. Acquired activated protein C resistance in pregnancy and association with increased thrombin generation and fetal weight. Lancet 1999; 23: 292-3.
10. De Visser MHC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
11. He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res 1999; 96: 145-56.
12. He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma-II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103: 355-61.
13. Antovic A, Blombäck M, Bremme K, He S. The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous throm-boembolism. Blood Coag Fibrinol 2002; 13: 181-6.
14. Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K, Kaider A. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100: 1060-2.
15. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to previously unrecognised mechanism characterised by a poor anti-coagulant response to activated protein C. Prediction of cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 94: 1004-8.
16. De Ronde H, Bertina M. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
17. Bokarewa MI, Blombäck M, Bremme K. Phospholipid antibodies and resistance to activated protein C in women with thrombophilia. Blood Coag Fibrinol 1995; 6: 417-22.
18. Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
19. Von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 30035-42.
20. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Besti-mung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
21. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
22. Bajzar L, Nesheim EM, Tracy BP. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 1996; 88: 2093-100.
23. Antovic JP, Blombäck M. Thrombin activatable fibrinolysis inhibitor (TAFI) antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation. Thromb Res 2002; 106: 59-62.